Cosmo Pharmaceuticals N.V. | Ownership
Companies that own Cosmo Pharmaceuticals N.V.
Schroder Investment Management Ltd.
520,750
3.46%
-150,000
0.05%
06/30/2018
AMG Fondsverwaltung AG
439,850
2.93%
46,921
7.59%
12/31/2017
UBS AG (Investment Management)
284,980
1.9%
11,074
0.03%
09/04/2018
The Vanguard Group, Inc.
180,470
1.2%
843
0%
07/31/2018
Baillie Gifford & Co.
175,763
1.17%
9,856
0.02%
04/30/2018
Norges Bank Investment Management
105,921
0.7%
-3,325
0%
12/31/2017
BlackRock Fund Advisors
83,986
0.56%
44
0%
09/06/2018
Credit Suisse Asset Management (Schweiz) AG
66,662
0.44%
-457
0.02%
05/31/2018
Zürcher Kantonalbank (Investment Management)
60,534
0.4%
2,714
0.02%
07/31/2018
AXA Investment Managers UK Ltd.
46,762
0.31%
483
0.03%
07/31/2018
| Address |
Riverside II
Dublin Dublin 2
Ireland
|
|
Employees
|
- |
| Website |
http://www.cosmopharma.com |
| Updated |
07/08/2019 |
| Cosmo Pharmaceuticals NV engages in the development, manufacturing and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland. . |
